Navigation Links
Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
Date:5/15/2012

WILMINGTON, Del., May 15, 2012 /PRNewswire/ -- Butamax™ Advanced Biofuels, LLC announced today that the United States Patent and Trademark Office (USPTO) has granted Butamax Patent Number 8,178,328. The '328 patent covers a highly efficient engineered pathway for producing isobutanol from recombinant microorganisms at commercial scale.  These novel microorganisms have been designed using advanced biotechnology to convert sugar to isobutanol.

(Logo: http://photos.prnewswire.com/prnh/20120209/MM50763LOGO )

The '328 patent also protects extraction and distillation of the isobutanol, as well as steps for recovering the solids (distillers grains) produced during isobutanol fermentation.  Protection of biobutanol processes that produce these grains is key in that distillers grains provide a significant economic advantage for Butamax's customers and provide local agriculture with a high-protein animal feed.  With these added protections having priority back to 2005, the '328 patent extends Butamax's foundational patent estate to span key value drivers for commercialization.

The USPTO granted the '328 patent in view of the art cited against Butamax's '188 and '899 patents in reexamination requests filed by Gevo.  This means that the USPTO has determined that the '328 patent is novel and inventive over all of the publications referenced in reexamination of the '188 and '889 patents.

"Grant of this new patent supports the Butamax view that the USPTO will ultimately affirm the '188 and '889 patents at the conclusion of the re-examination process," said Paul Beckwith, CEO Butamax.

Butamax will add the '328 patent to its ongoing litigation against Gevo.  A decision on Butamax's request for preliminary injunction against Gevo for infringing its '889 patent is expected in the near term and trial for that lawsuit (which also includes the '188 patent) is scheduled for April 2013; subsequent trials are expected for July 2014.

About Butamax

Butamax™ Advanced Biofuels, LLC, a joint venture between BP and DuPont, was formed to develop and commercialize biobutanol as a next generation renewable biofuel for the transport market. The company benefits from the synergy of DuPont's proven industrial biotechnology experience and BP's global fuels market knowledge. Butamax's proprietary technology offers a cost-advantaged manufacturing process for isobutanol with value from field to pump. For more information, visit www.butamax.com.

Butamax™ is a trademark of Butamax™ Advanced Biofuels, LLC.

Media Contact:
Cory Ziskind 646-277-1232


'/>"/>
SOURCE Butamax Advanced Biofuels, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Butamax™ Responds to Gevo Patent Infringement Lawsuit
2. Butamax™ and Fagen Announce Collaboration to Retrofit Ethanol Plants for Biobutanol Production
3. MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process
4. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
5. ScinoPharm Granted US Patent for Novel Crystal Forms
6. BioLife Solutions Granted European Biopreservation Patent
7. GeneNews granted U.S. patent for Chagas disease based on Sentinel Principle(TM) platform
8. Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
9. Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe
10. Crisis Exemption Granted to Market Avipel(R) Corn Seed Treatment in Louisiana
11. VIASPACE Granted US Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Israel , April 20, 2017  BrainStorm Cell Therapeutics ... technologies for neurodegenerative diseases, announced today that Chaim Lebovits ... Regenerative Medicine,s (ARM) 5 th Annual Cell & Gene ... EDT in Boston . In ... Officer & Chief Operating Officer, will participate in a panel ...
(Date:4/19/2017)... ... April 18, 2017 , ... Optofluidics today ... move comes after the company changed focus to making analytical tools for biopharmaceutical ... our new technology,” says CEO Robert Hart. Founders Bernardo Cordovez, Robert Hart and ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 A new ... Analysis and Industry Forecast, 2014-2022 ," the global market was valued at $6,769 ... a CAGR of 9.6% from 2016 to 2022. ... Allied ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:4/18/2017)... ... April 18, 2017 , ... METTLER TOLEDO Process ... concentration levels and vice-versa. , One of the key applications for the measurement ... control or monitoring. The principle of this analytical method is based on pure ...
Breaking Biology Technology:
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition and ... Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market ... CAGR of 29.63% between 2017 and 2022. Continue ... ... ...
Breaking Biology News(10 mins):